Somanetics Announces Share Repurchase Program Increased by $... (o identify cerebral orsomatic oxygen imb...)

Somanetics Announces Share Repurchase Program Increased by $15 Million

Date:5/9/2008

o identify cerebral or somatic oxygen imbalances and take necessary corrective action, potentially improving patient outcomes and reducing the costs of care. Somanetics supports its customers through a direct U.S. sales force and clinical education team. Covidien markets INVOS System products in Europe, Canada, the Middle East and South Africa and Edwards Lifesciences represents INVOS System products in Japan. For more information visit http://www.somanetics.com .

SOURCE Somanetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Somanetics Announces Share Repurchase Program
2. Somanetics Reports Financial Results for the First Quarter of Fiscal 2008
3. Somanetics Corporation to Release First Quarter 2008 Financial Results and Host Conference Call March 18, 2008
4. Somanetics Corporation to Release Fourth Quarter and Fiscal 2007 Financial Results and Host Conference Call January 23, 2008
5. Somanetics Corporation to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
7. China Medicine Announces Conference Call to Discuss First Quarter 2008 Results
8. Hooper Holmes Announces First Quarter 2008 Results
9. Bradmer announces 2008 first quarter operational and financial results
10. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
11. Team Finance LLC Announces First Quarter 2008 Results

Post Your Comments:

(Date:5/13/2008)...-- United American Healthcare,Corporation (Nasdaq:...nagement services to a full-service managed care o...l results for its third fiscal quarter,ended March... million for the third fiscal,quarter ended March ...or,the third quarter of the prior fiscal year. The...

(Date:5/13/2008)...re-FirstCall/ -- IRIDEX,Corporation (Nasdaq: IRIX...quarter of 2008 ended March 29, 2008., Revenue fo...8.7%,decrease from the $12.6 million reported for ...was $0.9 million or $0.10 per diluted share for th...f $4.9 million or $0.61 per,diluted share in the f...

(Date:5/13/2008)... Ongoing; Company Prepares for, Potential 2008 Lau...llion in Quarter, G...iddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ),...d commercializing novel anti-infective products, t...or the quarter ended March 31,2008., MiddleBrook...

(Date:5/13/2008)... the poor from improving, study finds , ,...of care at hospitals that treat poor and underserv... lagging well behind hospitals that do not serve t...tals, which rely on state and federal funding from... to improve the quality of care at the same rate t...

[0] United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results [0] IRIDEX Reports First Quarter 2008 Financial Results [0] MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results [0] Quality Lags at Safety-Net Hospitals

...Kashmiri separatist leader Syed Ali Shah Geelani, ...l documents to go to the US or Britain// for speci...action of the Hurriyat Conference underwent a biop...ations at the Apollo Hospital here Monday. "Docto...

...Scientists have found out that langerin, a protein...d the spread of HIV infection//. New transmission ...ivity of langerin. This research was conducted by ...y Medical Center in Amsterdam which was published ...

...The standard practice of giving oxygen to patients...rd Beasley from Medical Research Institute// of Ne...ly to bring more harm to the patients than good. ...ournal of the Royal Society of Medicine, professor...

...For patients with colorectal cancer who require th...tomy), an experimental procedure may decrease the ...procedure combines both the benefits of laparoscop...from NewYork-Presbyterian Hospital and its academi...

Other Medicine News:Health News:New Surgical Technique Decreases Colorectal OR Time 2

Cancer-hit Geelani to Travel Abroad for Specialized Treatment Protein Blockade For HIV Infection Oxygen Treatment To Cardiac Patients Questioned New Surgical Technique Decreases Colorectal OR Time

(Date:5/12/2008)... MDX-1100 at Digestive Disease Week .../- Medarex, Inc.,(Nasdaq: ...hase 2 clinical,development program of MDX-1100, a...10 (also known as IP-10), in ulcerative colitis (U...otentially treat UC and RA by,suppressing the infl...

(Date:5/12/2008)...ewswire/ -- GlaxoSmithKline (GSK),in collaboratio...ding,academic breast cancer research network, and ...r Cooperative Group (SOLTI), today announced the s... the role of TYKERB(R) in the,treatment of early b.../or,Trastuzumab Treatment Optimization) will evalu...

(Date:5/9/2008)... in national effort probing for,answers, By Joe...st, Pennsylvania Game Commission, NOTE: Photos...from the,Game Commission,s website (http://www.pg..., HARRISBURG, Pa., May 7 /PRNewswire-USNewswire/...elf on a new frontier: it is working with several,...

(Date:5/9/2008)...wire/ -- Osteoarthritis is a,painful and potential...illion people in the United States. It is caused b...ovel investigational pain medication,tapentadol, a...cant relief,for patients with joint-disease pain, ...ewer gastrointestinal side effects than those trea...

Breaking Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 2 Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 3 Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 4 TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2 TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3 TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4 TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5 TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6 TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7 White Nose Syndrome: Is Pennsylvania Next? 2 White Nose Syndrome: Is Pennsylvania Next? 3 White Nose Syndrome: Is Pennsylvania Next? 4 White Nose Syndrome: Is Pennsylvania Next? 5 White Nose Syndrome: Is Pennsylvania Next? 6 Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2 Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3 Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4 Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5 Members of Congress and Disability Rights Advocates Support the Restoration of the Americans with Disabilities Act and Welcome Back the Road To Freedo 6325 1 Members of Congress and Disability Rights Advocates Support the Restoration of the Americans with Disabilities Act and Welcome Back the Road To Freedo 6325 2 Members of Congress and Disability Rights Advocates Support the Restoration of the Americans with Disabilities Act and Welcome Back the Road To Freedo 6325 3 All Pets With Cancer in U S Provided Free Consultation 6323 1 All Pets With Cancer in U S Provided Free Consultation 6323 2 All Pets With Cancer in U S Provided Free Consultation 6323 3 All Pets With Cancer in U S Provided Free Consultation 6323 4 National Kidney Foundations 27th Annual Kidney Ball Featuring Entertainment by Patti LaBelle 6321 1 Lucian Leape Institute Announces First Roundtable 6319 1 Lucian Leape Institute Announces First Roundtable 6319 2 Lucian Leape Institute Announces First Roundtable 6319 3

[0] Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis [0] TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial [0] White Nose Syndrome: Is Pennsylvania Next?[0] Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile

...--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: P...ce(R)", today updated the progress of its Phase II...atic, unresectable,colorectal cancer patients who ...in, and its Phase II clinical trial for first-line...or both,indications may represent orphan drug stat...

..., 2007 - Late-breaking Phase III,clinical trial da...y on Thrombosis and Haemostasis (ISTH) Congress de...erior efficacy in the,prevention of venous thrombo...ment surgery in a head-to-head comparison with,eno... the RECORD3,(REgulation of Coagulation in major O...

Other Medicine Technology:Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 2 Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 3 Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 4 Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 5 Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2 Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3 Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4 Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5

Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

...Plate at Once , To increase efficiency and throug...t can adapt to the narrow well spacing. Thats exac...or., Available with Impact or Impact2 software (s...ly designed to allow you to transfer an entire col...

EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th

Designed to create a near bloodless field and provide myocardial protection during target vessel anastomosis. Its unique internal coil and tapered tip have been designed to allow easy, atraumatic ins

Medicine Products:

Impact2 16-Channel Electronic Pipettor, 2-125L Impact 16-Channel Electronic Pipettor, 1.0-30L EnTrust Dual Chamber ICD Axius™ Coronary Shunt

Somanetics Announces Share Repurchase Program Increased by $...(o identify cerebral orsomatic oxygen imb...),Health